NOVA:FRA
Novo Nordisk A/S
35,94 €
arrow_downward
−0,22%(−0,080) 1 p
6. nov, 22:00:00 GMT +1 · EUR
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse NOVA põhistatistika genereerimine…
Ava
35,60 €
Kõrge
36,20 €
Madal
35,60 €
Turu kapit.
138,20 mld
Keskm. maht
762,00
Maht
310,00
52 näd kõrgeim
54,80 €
52 näd madalaim
30,45 €
Töötajate arv
67 tuh
Ava
35,60 €
Kõrge
36,20 €
Madal
35,60 €
Turu kapit.
138,20 mld
Keskm. maht
762,00
Maht
310,00
52 näd kõrgeim
54,80 €
52 näd madalaim
30,45 €
Töötajate arv
67 tuh
Uudised
Veebiallikatest ja uudistepartneritelt
NAI500
·
37 minuti eest
Novo Nordisk’s 2026 Transition Year: Early Wegovy Pill Success Meets Weak Earnings and a Stock Down 20% Over Five Years
Seeking Alpha
·
2 tunni eest
Novo Nordisk reports liver improvements with Wegovy in some patients
Foreign Policy Journal
·
6 tunni eest
Novo Nordisk (NYSE: NVO) Shares Jump 6% After Strong Q3 Earnings Driven By Oral Weight-Loss Pill
Yahoo Finance
·
8 tunni eest
Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now?
Profiil
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 69,500 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Teave üksuse Novo Nordisk A/S kohta
TegevjuhtMike Doustdar
Töötajad66,7 tuh
Asutatud1923
PeakontoridBagsværd, Pealinna piirkond, Taani
SektorHealth Care
Valdkond-
Veebisaitnovonordisk.com